Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Why Active Funds May Underperform Benchmarks discusses persistent headwinds, costs, and timing issues that hinder outperformance.
26,804 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Oil prices surge as tensions around Iran intensify and the ceasefire appears cracking. Traders weigh supply disruptio...
TIAA’s CEO argues that leaders should rent the title, not own it, and invest in character traits that endure beyond a...
As inflation data fuels debate, analysts clash on the 2027 Social Security COLA, with projections split between 3.8% ...
When an energy storage company reports stronger results, the market often reacts with a sharp stock move. This guide ...
As existing-home prices hit record highs, builders in 10 U.S. metro areas are offering discounts on new homes. The mo...
A growing share of retirees claim Social Security at 62 while still working, triggering an earnings test that can dra...
Hycroft Mining stock is catching momentum as the company reports stronger gold and silver resources and clearer plans...
Struggling to keep a budget you can actually follow? This guide breaks budgeting tips into actionable steps with real...
Alphatec (ATEC) is navigating a shifting spine device market. This guide breaks down expected 2025 earnings, key driv...
A fresh take on dine brands (din) 2025, focusing on Q4 signals, brand momentum, and how investors can position themse...
A regional loan provider argues that trust and personal connection still drive loan success, releasing 2025 figures t...